These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 2209320)

  • 21. Effects of slow release bezafibrate on the lipid pattern and on blood glucose of type 2 diabetic patients with hyperlipidaemia.
    Rovellini A; Sommariva D; Branchi A; Maraffi F; Montalto C; Gandini R; Fasoli A
    Pharmacol Res; 1992 Apr; 25(3):237-45. PubMed ID: 1518767
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of bezafibrate on insulin secretion and peripheral insulin sensitivity in hyperlipidemic patients with and without diabetes.
    Riccardi G; Genovese S; Saldalamacchia G; Patti L; Marotta G; Postiglione A; Rivellese A; Capaldo B; Mancini M
    Atherosclerosis; 1989 Feb; 75(2-3):175-81. PubMed ID: 2653325
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Improvement of glucose tolerance by bezafibrate in non-obese patients with hyperlipidemia and impaired glucose tolerance.
    Inoue I; Takahashi K; Katayama S; Akabane S; Negishi K; Suzuki M; Ishii J; Kawazu S
    Diabetes Res Clin Pract; 1994 Oct; 25(3):199-205. PubMed ID: 7851275
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bezafibrate retard in type II diabetic patients: effects on hemostasis and glucose homeostasis.
    Mikhailidis DP; Mathur S; Barradas MA; Dandona P
    J Cardiovasc Pharmacol; 1990; 16 Suppl 9():platelet inhib/pd/ad/ae. PubMed ID: 1710742
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients.
    Miyazaki Y; Glass L; Triplitt C; Matsuda M; Cusi K; Mahankali A; Mahankali S; Mandarino LJ; DeFronzo RA
    Diabetologia; 2001 Dec; 44(12):2210-9. PubMed ID: 11793023
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome.
    Vega GL; Cater NB; Hadizadeh DR; Meguro S; Grundy SM
    Clin Pharmacol Ther; 2003 Sep; 74(3):236-44. PubMed ID: 12966367
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of added fat on plasma glucose and insulin response to ingested potato in individuals with NIDDM.
    Gannon MC; Ercan N; Westphal SA; Nuttall FQ
    Diabetes Care; 1993 Jun; 16(6):874-80. PubMed ID: 8325201
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bezafibrate reduces blood glucose in type 2 diabetes mellitus.
    Ogawa S; Takeuchi K; Sugimura K; Fukuda M; Lee R; Ito S; Sato T
    Metabolism; 2000 Mar; 49(3):331-4. PubMed ID: 10726910
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of effects of bezafibrate and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 and adipocytokine levels in dyslipidemic subjects with impaired glucose tolerance or type 2 diabetes mellitus: results from a crossover study.
    Noguchi T; Kobayashi J; Yagi K; Nohara A; Yamaaki N; Sugihara M; Ito N; Oka R; Kawashiri MA; Tada H; Takata M; Inazu A; Yamagishi M; Mabuchi H
    Atherosclerosis; 2011 Jul; 217(1):165-70. PubMed ID: 21411093
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of bezafibrate on insulin sensitivity and insulin secretion in non-obese Japanese type 2 diabetic patients.
    Taniguchi A; Fukushima M; Sakai M; Tokuyama K; Nagata I; Fukunaga A; Kishimoto H; Doi K; Yamashita Y; Matsuura T; Kitatani N; Okumura T; Nagasaka S; Nakaishi S; Nakai Y
    Metabolism; 2001 Apr; 50(4):477-80. PubMed ID: 11288046
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.
    Lund SS; Tarnow L; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag AA
    Eur J Endocrinol; 2008 Jan; 158(1):35-46. PubMed ID: 18166815
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bezafibrate. An update of its pharmacology and use in the management of dyslipidaemia.
    Goa KL; Barradell LB; Plosker GL
    Drugs; 1996 Nov; 52(5):725-53. PubMed ID: 9118820
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma insulin, C-peptide, and proinsulin concentrations in obese and nonobese individuals with varying degrees of glucose tolerance.
    Reaven GM; Chen YD; Hollenbeck CB; Sheu WH; Ostrega D; Polonsky KS
    J Clin Endocrinol Metab; 1993 Jan; 76(1):44-8. PubMed ID: 8421101
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Bezafibrate improves insulin resistance evaluated using the glucose clamp technique in patients with type 2 diabetes mellitus: a small-scale clinical study.
    Shiochi H; Ohkura T; Fujioka Y; Sumi K; Yamamoto N; Nakanishi R; Matsuzawa K; Izawa S; Ohkura H; Inoue K; Ueta E; Kato M; Taniguchi S; Yamamoto K
    Diabetol Metab Syndr; 2014; 6(1):113. PubMed ID: 25360162
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Simvastatin but not bezafibrate decreases plasma lipoprotein-associated phospholipase A₂ mass in type 2 diabetes mellitus: relevance of high sensitive C-reactive protein, lipoprotein profile and low-density lipoprotein (LDL) electronegativity.
    Constantinides A; de Vries R; van Leeuwen JJ; Gautier T; van Pelt LJ; Tselepis AD; Lagrost L; Dullaart RP
    Eur J Intern Med; 2012 Oct; 23(7):633-8. PubMed ID: 22902096
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes.
    Tan GD; Fielding BA; Currie JM; Humphreys SM; Désage M; Frayn KN; Laville M; Vidal H; Karpe F
    Diabetologia; 2005 Jan; 48(1):83-95. PubMed ID: 15619071
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Circulating lipids and cardiovascular risk in newly diagnosed non-insulin-dependent diabetic subjects in India.
    Shelgikar KM; Naik SS; Khopkar M; Bhat DS; Raut KN; Joglekar CV; Gerard ME; Yajnik CS
    Diabet Med; 1997 Sep; 14(9):757-61. PubMed ID: 9300225
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ketosis resistance in under thirty diabetic subjects.
    Sutradhar SR; Ali L; Khan AK; Siddiqui NI; Sarker CB; Rahman S; Huq MH; Debnath CR
    Mymensingh Med J; 2004 Jul; 13(2):134-7. PubMed ID: 15284687
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pronounced blood glucose-lowering effect of the antilipolytic drug acipimox in noninsulin-dependent diabetes mellitus patients during a 3-day intensified treatment period.
    Worm D; Henriksen JE; Vaag A; Thye-Rønn P; Melander A; Beck-Nielsen H
    J Clin Endocrinol Metab; 1994 Mar; 78(3):717-21. PubMed ID: 8126147
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diurnal variation of blood ketone bodies in insulin-dependent diabetes mellitus and noninsulin-dependent diabetes mellitus patients: the relationship to serum C-peptide immunoreactivity and free insulin.
    Ubukata E
    Ann Nutr Metab; 1990; 34(6):333-42. PubMed ID: 2076025
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.